asparaginase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5070 9015-68-3

Description:

MoleculeDescription

Synonyms:

  • asparaginase
  • elspar
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Feb. 1, 1994 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 560.41 40.21 243 5170 158106 90464928
Venoocclusive liver disease 284.32 40.21 67 5346 5926 90617108
Posterior reversible encephalopathy syndrome 212.96 40.21 71 5342 22268 90600766
Osteonecrosis 201.76 40.21 71 5342 26170 90596864
Lennox-Gastaut syndrome 192.30 40.21 30 5383 275 90622759
Temporal lobe epilepsy 161.27 40.21 27 5386 398 90622636
Neutropenia 152.86 40.21 118 5295 224786 90398248
Haematotoxicity 152.67 40.21 48 5365 12487 90610547
Pneumatosis intestinalis 140.04 40.21 34 5379 3403 90619631
Human bocavirus infection 138.00 40.21 24 5389 448 90622586
Acute lymphocytic leukaemia recurrent 137.30 40.21 32 5381 2689 90620345
Neurotoxicity 123.75 40.21 47 5366 21420 90601614
Secondary immunodeficiency 117.90 40.21 27 5386 2099 90620935
Enterobacter infection 107.52 40.21 26 5387 2557 90620477
Drug interaction 99.09 40.21 101 5312 276352 90346682
Gastroenteritis norovirus 94.22 40.21 23 5390 2353 90620681
Bone marrow failure 92.66 40.21 43 5370 32178 90590856
Human herpesvirus 6 infection 90.57 40.21 24 5389 3408 90619626
Venous thrombosis 87.87 40.21 26 5387 5511 90617523
Philadelphia chromosome positive 84.92 40.21 16 5397 474 90622560
Herpes simplex 83.76 40.21 29 5384 10152 90612882
Encephalopathy 77.78 40.21 43 5370 46401 90576633
Rhinovirus infection 77.46 40.21 24 5389 5939 90617095
Partial seizures 76.85 40.21 25 5388 7235 90615799
Mucormycosis 74.23 40.21 21 5392 3800 90619234
Drug resistance 73.40 40.21 36 5377 30413 90592621
Clostridium difficile colitis 68.66 40.21 33 5380 26673 90596361
Enteritis 68.24 40.21 25 5388 10296 90612738
Second primary malignancy 68.10 40.21 25 5388 10353 90612681
T-cell lymphoma refractory 67.96 40.21 10 5403 59 90622975
Pharyngeal inflammation 67.10 40.21 15 5398 1045 90621989
Escherichia bacteraemia 65.82 40.21 21 5392 5714 90617320
Therapeutic response delayed 64.74 40.21 14 5399 836 90622198
Hyperammonaemia 63.31 40.21 21 5392 6454 90616580
Hepatotoxicity 62.18 40.21 37 5376 45805 90577229
Neuropathy peripheral 62.05 40.21 57 5356 136913 90486121
Cerebral venous sinus thrombosis 59.77 40.21 16 5397 2360 90620674
Sepsis 59.45 40.21 63 5350 179751 90443283
Hypertriglyceridaemia 59.25 40.21 21 5392 7868 90615166
Tumour lysis syndrome 59.18 40.21 23 5390 11129 90611905
Cystitis bacterial 57.92 40.21 11 5402 340 90622694
Thrombocytopenia 51.77 40.21 63 5350 208662 90414372
Ileus paralytic 51.75 40.21 17 5396 5068 90617966
Aplasia 51.57 40.21 16 5397 3975 90619059
Neutropenic colitis 50.98 40.21 16 5397 4127 90618907
Cerebral venous thrombosis 50.73 40.21 14 5399 2314 90620720
Multiple organ dysfunction syndrome 48.75 40.21 37 5376 68299 90554735
Bacterial infection 48.51 40.21 25 5388 23419 90599615
Pain 47.84 40.21 3 5410 996338 89626696
Glioblastoma multiforme 47.15 40.21 11 5402 927 90622107
Pleuroparenchymal fibroelastosis 43.68 40.21 8 5405 202 90622832
Glioma 43.54 40.21 9 5404 432 90622602
Neoplasm recurrence 41.83 40.21 13 5400 3246 90619788
Pancytopenia 41.25 40.21 43 5370 120220 90502814
Myelopathy 41.12 40.21 13 5400 3431 90619603
Febrile bone marrow aplasia 40.98 40.21 17 5396 9721 90613313

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 344.42 30.10 285 7979 185418 42427653
Posterior reversible encephalopathy syndrome 272.52 30.10 100 8164 12721 42600350
Neutropenia 194.43 30.10 215 8049 199216 42413855
Venoocclusive liver disease 192.00 30.10 73 8191 10229 42602842
Haematotoxicity 187.44 30.10 73 8191 10912 42602159
Osteonecrosis 142.75 30.10 67 8197 15798 42597273
Multiple-drug resistance 133.22 30.10 51 8213 7271 42605800
Glioblastoma multiforme 99.83 30.10 25 8239 857 42612214
Acute lymphocytic leukaemia recurrent 94.20 30.10 33 8231 3658 42609413
Glioma 91.81 30.10 21 8243 485 42612586
Brain sarcoma 89.99 30.10 14 8250 29 42613042
Septic shock 89.19 30.10 99 8165 91573 42521498
Mucormycosis 86.02 30.10 37 8227 7106 42605965
Bone marrow failure 85.24 30.10 62 8202 33031 42580040
Cerebellar tumour 80.30 30.10 15 8249 120 42612951
Stomatitis 77.90 30.10 70 8194 50259 42562812
Mucosal inflammation 73.14 30.10 67 8197 49307 42563764
Multiple organ dysfunction syndrome 69.99 30.10 90 8174 96945 42516126
Leukaemia recurrent 64.56 30.10 21 8243 1855 42611216
Cerebral venous thrombosis 63.05 30.10 18 8246 1023 42612048
Encephalopathy 62.98 30.10 57 8207 41276 42571795
Neurotoxicity 60.17 30.10 44 8220 23607 42589464
Myelopathy 59.33 30.10 22 8242 2869 42610202
Haemophagocytic lymphohistiocytosis 58.26 30.10 39 8225 18183 42594888
Venoocclusive disease 56.25 30.10 23 8241 3892 42609179
Fatigue 55.66 30.10 9 8255 435632 42177439
Minimal residual disease 52.72 30.10 14 8250 607 42612464
Hyperammonaemia 52.16 30.10 27 8237 7839 42605232
Aspergillus infection 50.88 30.10 34 8230 15803 42597268
Candida infection 50.05 30.10 38 8226 21572 42591499
Aspiration bone marrow abnormal 49.49 30.10 10 8254 125 42612946
Bronchopulmonary aspergillosis 49.09 30.10 36 8228 19393 42593678
Cerebral candidiasis 48.18 30.10 9 8255 72 42612999
Systemic candida 46.38 30.10 22 8242 5297 42607774
Candida endophthalmitis 42.71 30.10 9 8255 140 42612931
Calculus urinary 42.13 30.10 15 8249 1742 42611329
Cerebral venous sinus thrombosis 41.10 30.10 12 8252 739 42612332
Pancreatitis acute 41.04 30.10 41 8223 33523 42579548
Hydrocephalus 40.69 30.10 21 8243 6057 42607014
Fungal infection 39.85 30.10 32 8232 19690 42593381
Drug clearance decreased 38.99 30.10 15 8249 2163 42610908
Enamel anomaly 38.40 30.10 9 8255 232 42612839
Hypertriglyceridaemia 38.07 30.10 24 8240 10102 42602969
Tooth hypoplasia 37.72 30.10 9 8255 251 42612820
Pseudohyponatraemia 37.58 30.10 8 8256 131 42612940
Hepatotoxicity 36.93 30.10 34 8230 25133 42587938
Second primary malignancy 36.77 30.10 23 8241 9552 42603519
Intracranial pressure increased 36.72 30.10 18 8246 4656 42608415
Respiratory moniliasis 36.68 30.10 9 8255 283 42612788
Pancytopenia 36.01 30.10 74 8190 117669 42495402
Large intestine infection 35.81 30.10 14 8250 2107 42610964
Hepatic steatosis 35.48 30.10 31 8233 21417 42591654
Hepatic calcification 35.16 30.10 9 8255 337 42612734
Herpes simplex 34.93 30.10 20 8244 7075 42605996
Seizure 34.81 30.10 74 8190 120487 42492584
Hepatocellular injury 34.77 30.10 32 8232 23646 42589425
Leukopenia 34.29 30.10 56 8208 74690 42538381
Systemic mycosis 34.21 30.10 14 8250 2373 42610698
Infection 33.76 30.10 70 8194 111998 42501073
Acute monocytic leukaemia 33.76 30.10 9 8255 396 42612675
Pyrexia 33.61 30.10 158 8106 393884 42219187
Stomatococcal infection 33.53 30.10 8 8256 223 42612848
Acute graft versus host disease in intestine 33.41 30.10 16 8248 3935 42609136
Adrenomegaly 33.14 30.10 9 8255 425 42612646
Costal cartilage fracture 33.03 30.10 8 8256 238 42612833
Metamyelocyte count increased 32.47 30.10 9 8255 459 42612612
Blast cells present 31.65 30.10 9 8255 504 42612567
Myelosuppression 31.45 30.10 39 8225 40422 42572649
Hepatitis E 30.54 30.10 14 8250 3120 42609951
Superior sagittal sinus thrombosis 30.39 30.10 8 8256 335 42612736
Diarrhoea 30.28 30.10 27 8237 460822 42152249
Sepsis 30.19 30.10 96 8168 199238 42413833

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 808.36 29.80 514 14604 316253 110257928
Secondary immunodeficiency 530.35 29.80 124 14994 4552 110569629
Posterior reversible encephalopathy syndrome 451.75 29.80 171 14947 33690 110540491
Haematotoxicity 323.36 29.80 118 15000 20964 110553217
Bacterial infection 310.55 29.80 143 14975 45893 110528288
Neutropenia 308.93 29.80 314 14804 374306 110199875
Human bocavirus infection 286.20 29.80 58 15060 1070 110573111
Human herpesvirus 6 infection 275.64 29.80 79 15039 6502 110567679
Mycobacterium chelonae infection 268.60 29.80 66 15052 2994 110571187
Osteonecrosis 266.34 29.80 117 15001 33624 110540557
Cystitis bacterial 239.76 29.80 51 15067 1202 110572979
Thymus hypoplasia 219.26 29.80 50 15068 1637 110572544
Norovirus test positive 217.42 29.80 45 15073 925 110573256
Lymphoid tissue hypoplasia 214.53 29.80 49 15069 1616 110572565
Pneumatosis intestinalis 213.88 29.80 69 15049 8460 110565721
Aspergillus infection 209.20 29.80 91 15027 25525 110548656
Enterobacter infection 204.72 29.80 61 15057 5750 110568431
Acute lymphocytic leukaemia recurrent 200.63 29.80 60 15058 5727 110568454
Pseudomonal sepsis 193.90 29.80 65 15053 8981 110565200
Viral infection 193.82 29.80 109 15009 53030 110521151
Bronchopulmonary aspergillosis 189.62 29.80 89 15029 29774 110544407
Clostridium difficile colitis 187.88 29.80 100 15018 43678 110530503
Neurotoxicity 182.79 29.80 97 15021 42110 110532071
Viraemia 175.17 29.80 50 15068 4052 110570129
Bone marrow failure 169.59 29.80 103 15015 57745 110516436
Rhinovirus infection 166.03 29.80 62 15056 11727 110562454
Parainfluenzae virus infection 153.00 29.80 51 15067 6923 110567258
Glioblastoma multiforme 145.37 29.80 35 15083 1455 110572726
Multiple-drug resistance 141.57 29.80 57 15061 13178 110561003
Glioma 135.45 29.80 30 15088 858 110573323
Enteritis 127.50 29.80 59 15059 19097 110555084
Hepatotoxicity 127.17 29.80 89 15029 63311 110510870
Cerebral venous thrombosis 126.98 29.80 37 15081 3225 110570956
Encephalopathy 120.44 29.80 95 15023 80960 110493221
Multiple organ dysfunction syndrome 118.84 29.80 124 14994 151586 110422595
Septic shock 116.72 29.80 125 14993 157403 110416778
Mucormycosis 114.45 29.80 46 15072 10582 110563599
Abscess bacterial 107.00 29.80 25 15093 912 110573269
Leukaemia recurrent 106.52 29.80 32 15086 3099 110571082
Fatigue 104.59 29.80 20 15098 1215938 109358243
Hyperammonaemia 103.09 29.80 46 15072 13686 110560495
Brain sarcoma 101.67 29.80 15 15103 31 110574150
Myelopathy 99.74 29.80 35 15083 5541 110568640
Diffuse alveolar damage 98.43 29.80 32 15086 4015 110570166
Neuropathy peripheral 97.03 29.80 121 14997 179156 110395025
Cytomegalovirus chorioretinitis 94.95 29.80 36 15082 7092 110567089
Cytomegalovirus viraemia 94.75 29.80 47 15071 17717 110556464
Second primary malignancy 94.00 29.80 47 15071 18021 110556160
Hypertriglyceridaemia 92.92 29.80 45 15073 16109 110558072
Fungal infection 91.93 29.80 67 15051 50739 110523442
Coronavirus infection 91.47 29.80 38 15080 9507 110564674
Mucosal inflammation 90.76 29.80 87 15031 96054 110478127
Venoocclusive disease 87.96 29.80 33 15085 6317 110567864
Cerebral venous sinus thrombosis 87.43 29.80 27 15091 2868 110571313
Cerebellar tumour 86.56 29.80 16 15102 177 110574004
Herpes simplex 84.94 29.80 42 15076 15722 110558459
Pain 83.54 29.80 15 15103 954940 109619241
Sepsis 80.23 29.80 153 14965 327193 110246988
Haemophagocytic lymphohistiocytosis 74.45 29.80 49 15069 31510 110542671
Lennox-Gastaut syndrome 73.04 29.80 15 15103 296 110573885
Pancytopenia 72.32 29.80 114 15004 209499 110364682
Oesophageal candidiasis 72.03 29.80 34 15084 11500 110562681
Candida infection 70.70 29.80 56 15062 47953 110526228
Malaise 69.72 29.80 6 15112 671813 109902368
Intracardiac thrombus 69.55 29.80 25 15093 4243 110569938
Venous thrombosis 68.71 29.80 30 15088 8475 110565706
Oral herpes 66.21 29.80 48 15070 36032 110538149
Tumour lysis syndrome 65.87 29.80 45 15073 30756 110543425
Pancreatitis acute 65.47 29.80 59 15059 60215 110513966
Neoplasm recurrence 64.59 29.80 25 15093 5207 110568974
Philadelphia chromosome positive 62.02 29.80 16 15102 884 110573297
Seizure 61.21 29.80 109 15009 221076 110353105
Fusarium infection 59.72 29.80 20 15098 2751 110571430
Pleuroparenchymal fibroelastosis 59.44 29.80 13 15105 350 110573831
Thrombocytopenia 58.73 29.80 140 14978 348745 110225436
Disseminated aspergillosis 57.85 29.80 19 15099 2461 110571720
Drug resistance 56.97 29.80 53 15065 56321 110517860
Temporal lobe epilepsy 55.35 29.80 13 15105 485 110573696
Aplasia 54.73 29.80 25 15093 7848 110566333
Escherichia bacteraemia 54.52 29.80 27 15091 10137 110564044
T-cell lymphoma refractory 54.23 29.80 10 15108 109 110574072
Leukoencephalopathy 54.04 29.80 26 15092 9169 110565012
Ileus paralytic 53.69 29.80 28 15090 11709 110562472
Dizziness 52.90 29.80 15 15103 698178 109876003
Cerebral candidiasis 51.32 29.80 9 15109 72 110574109
Inappropriate antidiuretic hormone secretion 50.94 29.80 40 15078 33811 110540370
Dyspnoea 50.91 29.80 46 15072 1106826 109467355
Diarrhoea 50.48 29.80 49 15069 1139456 109434725
Hepatocellular injury 50.00 29.80 47 15071 50595 110523586
Cardiac ventricular thrombosis 49.65 29.80 18 15100 3129 110571052
Arthralgia 48.54 29.80 23 15095 779609 109794572
Pharyngeal inflammation 47.63 29.80 15 15103 1699 110572482
Hepatic steatosis 47.60 29.80 45 15073 48786 110525395
Gastroenteritis norovirus 47.24 29.80 18 15100 3593 110570588
Lymphopenia 46.96 29.80 41 15077 40129 110534052
Therapeutic response delayed 46.39 29.80 14 15104 1376 110572805
Systemic candida 46.21 29.80 24 15094 9950 110564231
Leukopenia 45.95 29.80 77 15041 148714 110425467
Febrile bone marrow aplasia 45.83 29.80 29 15089 17436 110556745
Intracranial pressure increased 44.98 29.80 24 15094 10511 110563670
Neutropenic colitis 44.97 29.80 22 15096 8043 110566138
Encephalitis 43.82 29.80 29 15089 18810 110555371
Candida endophthalmitis 42.59 29.80 9 15109 205 110573976
Hydrocephalus 42.51 29.80 23 15095 10352 110563829
Pneumonia fungal 42.51 29.80 26 15092 14728 110559453
Drug clearance decreased 41.49 29.80 17 15101 4105 110570076
Haemangioma 40.33 29.80 15 15103 2801 110571380
Bacterial sepsis 39.65 29.80 22 15096 10404 110563777
Cardiotoxicity 39.29 29.80 26 15092 16855 110557326
Calculus urinary 38.69 29.80 15 15103 3137 110571044
Alopecia 38.50 29.80 3 15115 364750 110209431
Pancreatitis 38.09 29.80 55 15063 93478 110480703
Tooth hypoplasia 38.01 29.80 9 15109 348 110573833
Insomnia 37.97 29.80 3 15115 360587 110213594
Partial seizures 37.91 29.80 22 15096 11327 110562854
Hepatic calcification 37.81 29.80 9 15109 356 110573825
Blast cells present 37.65 29.80 11 15107 967 110573214
Aplastic anaemia 37.17 29.80 29 15089 24279 110549902
Pseudohyponatraemia 37.15 29.80 8 15110 200 110573981
Enterococcal infection 37.15 29.80 27 15091 20339 110553842
Venoocclusive liver disease 36.80 29.80 24 15094 15183 110558998
Acute graft versus host disease in intestine 36.37 29.80 17 15101 5622 110568559
Cell death 35.94 29.80 17 15101 5774 110568407
Enamel anomaly 35.88 29.80 8 15110 236 110573945
Superior sagittal sinus thrombosis 35.86 29.80 11 15107 1142 110573039
Pseudomonas infection 35.76 29.80 30 15088 27823 110546358
Weight increased 35.73 29.80 7 15111 419637 110154544
Neurological examination abnormal 35.60 29.80 10 15108 764 110573417
Respiratory moniliasis 35.59 29.80 9 15109 459 110573722
Costal cartilage fracture 35.34 29.80 8 15110 253 110573928
Hyperbilirubinaemia 35.24 29.80 31 15087 30640 110543541
Adrenomegaly 35.16 29.80 9 15109 482 110573699
Myelosuppression 34.86 29.80 53 15065 94287 110479894
Picornavirus infection 33.62 29.80 7 15111 148 110574033
Minimal residual disease 33.54 29.80 10 15108 943 110573238
Pulmonary haemorrhage 32.73 29.80 23 15095 16433 110557748
Systemic mycosis 32.54 29.80 14 15104 3815 110570366
Hepatosplenic candidiasis 32.44 29.80 9 15109 657 110573524
Stomatococcal infection 32.18 29.80 8 15110 380 110573801
Metamyelocyte count increased 31.92 29.80 9 15109 697 110573484
Escherichia infection 31.29 29.80 26 15092 23790 110550391
Acute graft versus host disease in skin 31.13 29.80 19 15099 10721 110563460
Hypofibrinogenaemia 31.02 29.80 12 15106 2495 110571686
Hepatitis E 30.49 29.80 14 15104 4445 110569736
Large intestine infection 30.39 29.80 14 15104 4478 110569703
Astrocytoma 30.02 29.80 7 15111 253 110573928
Blood bilirubin increased 29.95 29.80 44 15074 75928 110498253

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA CS M0001815 Asparaginase
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000175669 Asparagine-specific Enzyme
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs
adagrasibafliberceptaltretamineamsacrineanagrelidearsenic trioxidebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitoxeflornithine show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute lymphoid leukemia indication 91857003 DOID:9952




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
G4FQ3CKY5R UNII
4017974 VANDF
C0003993 UMLSCUI
CHEBI:753896 CHEBI
CHEMBL2108989 ChEMBL_ID
DB00023 DRUGBANK_ID
D001215 MESH_DESCRIPTOR_UI
1156 RXNORM
4222 MMSL
688 MMSL
002673 NDDF
18811003 SNOMEDCT_US
370969007 SNOMEDCT_US
371014004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rylaze HUMAN PRESCRIPTION DRUG LABEL 1 68727-900 INJECTION 20 mg INTRAMUSCULAR BLA 24 sections